Technology
Health
Pharmaceutical

Allergan

$140.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.16 (0.11%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Allergan and other stocks, options, ETFs, and crypto commission-free!

About

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. Read More The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Employees
16,900
Headquarters
Dublin, Dublin
Founded
1984
Market Cap
45.96B
Price-Earnings Ratio
Dividend Yield
2.15
Average Volume
2.35M
High Today
$143.86
Low Today
$138.76
Open Price
$138.77
Volume
768.07K
52 Week High
$197.00
52 Week Low
$125.84

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Europe (Non-UK)
Europe

News

Seeking Alpha15h

Allergan And Cenicriviroc In NASH: The Forgotten

Overall, this weekly newsletter provides news-related events on stocks focused on the development of liver therapeutics. For accelerated conditional approval on FDA Subpart H, cenicriviroc must achieve the primary clinical endpoint of ≥1 stage improvement in liver fibrosis without worsening of NASH at 12 months. The top-line Phase 3 interim data readout on the 52-week study of cenicriviroc in patients with biopsied NASH fibrosis should be announced by Q4 2020. Allergan’s lead investigative drug candidate...

14
ReutersMay 17

Allergan wins less than $50,000 in case against compounder Imprimis

A federal jury on Thursday awarded Allergan PLC less than $50,000 of the millions of dollars it sought in a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling certain compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan’s dry eye drug Restasis, according to a lawyer for Imprimis.

20
Yahoo FinanceMay 15

Allergan to Present VRAYLAR® (cariprazine) Data at the American Psychiatric Association 2019 Annual Meeting Highlighting Continued Commitment to Mental Health

Abstracts will showcase research on VRAYLAR, including a focus on an investigational use for the treatment of bipolar depression FDA action on supplemental New Drug Application (sNDA) for VRAYLAR for the treatment of bipolar depression is expected in first half this year DUBLIN, May 15, 2019 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, today announced it will showcase data during the upcoming American Psychiatric Association (APA) Annual Meeting in San Francisco, May 18 – M...

0

Earnings

$3.36
$3.86
$4.36
$4.86
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
$3.55 per share
Actual
$3.79 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.